Amgen, Inc.
šŗšøUnited States
- Country
- šŗšøUnited States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluating AranespĀ® in Subjects With End Stage Renal Disease onChronic Hemodialysis
Phase 4
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117104
SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 673
- Registration Number
- NCT00117052
Study of Transplant Related Anemia Treated With AranespĀ® (STRATA)
Phase 4
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117065
A Study to Evaluate the Effectiveness of AranespĀ® for Cancer Patients With Anemia
Phase 4
Completed
- Conditions
- AnemiaNeoplasms
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1500
- Registration Number
- NCT00117039
AranespĀ® Monthly Preference Study - 2
Phase 4
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2008-09-30
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117078
Anakinra (KineretĀ®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117091
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
Phase 3
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00116701
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Phase 3
Completed
- Conditions
- ThrombocytopeniaIdiopathic Thrombocytopenic Purpura
- Interventions
- Biological: Romiplostim
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 313
- Registration Number
- NCT00116688
Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: DMARD
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4968
- Registration Number
- NCT00116714
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5103
- Registration Number
- NCT00116727
Ā© Copyright 2025. All Rights Reserved by MedPath